Results 11 to 20 of about 552 (131)

Rationality of routine clinical use of olokizumab in COVID-19

Качественная клиническая практика, 2020
Routine clinical use of olokizumab in COVID-19 is not recommended. The use of olokizumab is possible in clinical trials.
V. M. Tsvetov, A. V. Matveev, D. A. Sychev   +2 more
doaj   +3 more sources

Experience of olokizumab use in COVID-19 patients

Терапевтический архив, 2020
Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the cytokine storm.
V. N. Antonov, G. L. Ignatova, O. V. Pribytkova, S. S. Sleptsova, E. A. Strebkova, E. A. Khudyakova, A. I. Simakov, S. Yu. Rabets, E. P. Tikhonova, D. Yu. Kurmaeva, M. A. Petrushin, A. S. Mashkov, E. V. Gayazova, I. V. Yasheva, M. A. Andreev, V. V. Khinovker, A. Yu. Karpunin, B. V. Berezhanskiy   +17 more
doaj   +4 more sources

Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment [PDF]

Journal of Personalized Medicine, 2020
Rheumatoid arthritis (RA) is the most common autoimmune disease worldwide. Epigenetic alternations of microRNAs (miRNAs) can contribute to its pathogenesis and progression. As the first line therapy with DMARDs is not always successful, other drugs and therapeutic targets should be applied.
D S Mikhaylenko, Ekaterina B Kuznetsova, Alexey I Kalinkin   +2 more
exaly   +5 more sources

CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19

Фармация и фармакология (Пятигорск), 2022
The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.Materials and methods.
E. V. Tavlueva, E. V. Zernova, M. P. Kutepova, N. E. Kostina, V. S. Lesina, D. R. Mould, K. Ito, A. V. Zinchenko, A. N. Dolgorukova, M. V. Nikolskaya, M. S. Lemak, O. V. Filon, M. Yu. Samsonov   +12 more
doaj   +2 more sources

Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis

Научно-практическая ревматология, 2022
Treatment algorithms for systemic sclerosis have not been completely developed. Effectivity of medications are usually used in clinical practice has a low level of evidence.
E. S. Kuvardin, D. Yu. Andreev, P. A. Yastrebov, V. Yu. Myachikova, D. V. Bukhanova, D. V. Karpova, K. N. Malikov, M. Yu. Samsonov, A. L. Maslyanskiy   +8 more
doaj   +2 more sources

Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study

Научно-практическая ревматология, 2023
Background. Interleukin (IL) 6 plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors (i) used to treat RA patients may have an antidepressant effect.Objective – to evaluate the effectiveness of ...
T. A. Lisitsyna, A. A. Abramkin, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, A. B. Borisova, V. G. Ignatiev, E. L. Nasonov   +7 more
doaj   +3 more sources

Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy

Научно-практическая ревматология, 2023
The aim of the study was to investigate the dynamics of clinical and laboratory parameters of inflammatory disease activity and cytokines in patients with rheumatoid arthritis (RA) against the background of olokizumab (OKZ) treatment.Materials and ...
N. A. Lapkina, A. A. Baranov, N. Yu. Levshin, A. A. Kolinko, L. A. Mineeva, A. S. Artyuhov, E. L. Nasonov   +6 more
doaj   +2 more sources

Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia

Фундаментальная и клиническая медицина, 2020
Aim. To study the efficiency of IL-6 inhibitor olokizumab in suppressing the inflammation and improving treatment outcomes in patients with moderate COVID-19 pneumonia. Materials and Methods.
N. G. Ganyukova, M. I. Likstanov, M. V. Kosinova, I. N. Kushnir, V. G. Moses, K. B. Moses   +5 more
doaj   +3 more sources

Olokizumab in patients with inflammatory phenotype of osteoarthritis, treatment experience

Современная ревматология
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with knee osteoarthritis (OA) with synovitis, persistent pain and ineffectiveness of previous conservative therapy.   Material and methods.
A. M. Lila, L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, E. P. Sharapova, E. A. Strebkova, N. M. Savushkina, A. R. Khalmetova, V. A. Nesterenko, A. S. Avdeeva, E. Yu. Samarkina, M. E. Diatroptov, O. G. Alekseeva   +12 more
doaj   +2 more sources

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan

Современная ревматология
Objective: to assess the efficacy and safety of olokizumab (OKZ) in routine clinical practice in patients with rheumatoid arthritis (RA) in Kazakhstan.Material and methods.
G. A. Togizbayev, D. I. Parpiyeva, D. A. Maksot   +2 more
doaj   +3 more sources